Inaccurate Glucose Sensor Values After Hydroxyurea Administration.

abstract：:Chronic hyperglycemia, as assessed by hemoglobin A1c (HbA1c) levels, has been associated with the development of microvascular and macrovascular complications of diabetes. Several studies have shown that acute hyperglycemia can add to the effect of chronic hyperglycemia in inducing tissue damage. Acute hyperglycemia c...

journal_title：Diabetes technology & therapeutics

authors： Marcovecchio ML,Lucantoni M,Chiarelli F

更新日期：2011-03-01 00:00:00

abstract：:Glucose oxidase has had a central role in previous glucose sensing methods and is key to the development of certain new glucose sensors. The immobilized enzyme is specific for glucose and sufficiently long-lived for many sensor applications, but new glucose sensing applications may place increased demands on the enzym...

journal_title：Diabetes technology & therapeutics

authors： Gough DA,Bremer T

更新日期：2000-10-01 00:00:00

abstract：BACKGROUND:We assessed the impact of using an automated bolus advisor integrated into a blood glucose meter on the timing and frequency of adjusting insulin therapy parameter settings and whether the availability of this technology would increase blood glucose test strip utilization in diabetes patients treated with mu...

journal_title：Diabetes technology & therapeutics

authors： Cavan DA,Ziegler R,Cranston I,Barnard K,Ryder J,Vogel C,Parkin CG,Koehler W,Vesper I,Petersen B,Schweitzer MA,Wagner RS

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:There are currently few data available on the long-term use of continuous subcutaneous insulin infusion (CSII) (insulin pump) therapy in children. METHODS:Charts from 291 youth with type 1 diabetes (T1D) who were treated with CSII therapy for at least 1 year were reviewed. Data analysis included hemoglobin ...

journal_title：Diabetes technology & therapeutics

authors： Scrimgeour L,Cobry E,McFann K,Burdick P,Weimer C,Slover R,Chase HP

更新日期：2007-10-01 00:00:00

abstract：:Innovo (Novo Nordisk A/S, Hillerød, Denmark) is a new insulin injection system that offers built-in memory and a large, clear display to provide patients with more control during insulin injections. The aim of this trial was to compare the efficacy and safety of Innovo and NovoPen 3 (Novo Nordisk A/S) in patients expe...

journal_title：Diabetes technology & therapeutics

authors： Valk NK,Cerny G,Sieber J,Lytzen L,Berg B

更新日期：2004-02-01 00:00:00

abstract：BACKGROUND:Patients with diabetes do daily self-monitoring of blood glucose (SMBG). For such patients, we devised an engine that predicts not only the expected blood glucose level at the next meal but also the pending risks of hypoglycemia. The purpose of this study was to validate the predictions and provide evidence ...

journal_title：Diabetes technology & therapeutics

authors： Albisser AM,Sakkal S,Wright C

更新日期：2005-06-01 00:00:00

abstract：BACKGROUND:Type 1 diabetic patients have high instability of daily glucose levels. The aim of this study was to evaluate the long-term effects of continuous subcutaneous insulin infusion (CSII) therapy, compared with multiple daily injections of insulin (MDI), on glucose variability, in young type 1 diabetic patients t...

journal_title：Diabetes technology & therapeutics

authors： Maiorino MI,Bellastella G,Casciano O,Cirillo P,Simeon V,Chiodini P,Petrizzo M,Gicchino M,Romano O,Caruso P,Giugliano D,Esposito K

更新日期：2018-02-01 00:00:00

abstract：OBJECTIVE:This study was designed to develop predictive formulas for precise insulin dosing in young children with type 1 diabetes (T1DM). RESEARCH DESIGN AND METHODS:Consecutive 1-year data from a group of 14 young patients (eight girls, six boys) 3.9 ± 0.8 years old with diabetes duration of 2.0 ± 0.8 years, transit...

journal_title：Diabetes technology & therapeutics

authors： Alemzadeh R,Hoffmann RG,Dasgupta M,Parton E

更新日期：2012-05-01 00:00:00

abstract：:AIDA is a diabetes-computing program freely available from www.2aida.org on the Web. The software is intended to serve as an educational support tool, and can be used by anyone who has an interest in diabetes, whether they be patients, relatives, health-care professionals, or students. In previous "Diabetes Informatio...

journal_title：Diabetes technology & therapeutics

authors： Lehmann ED

更新日期：2003-01-01 00:00:00

abstract：AIM:Insulin therapy induces remission in subjects with newly diagnosed type 2 diabetes mellitus (T2DM). This study assessed the insulin and C-peptide levels in newly diagnosed T2DM subjects during low-dose insulin therapy. SUBJECTS AND METHODS:Twenty newly diagnosed, drug-naive, T2DM patients without acute or chronic ...

journal_title：Diabetes technology & therapeutics

authors： Bhattacharya S,Ammini AC,Jyotsna V,Gupta N,Dwivedi S

更新日期：2011-04-01 00:00:00

abstract：AIMS:This study evaluated treatment satisfaction, comfort, and function using the wireless OmniPod™ Insulin Management System (Insulet Corp., Bedford, MA) compared with conventional (infusion set) insulin pumps in young adults with type 1 diabetes. RESEARCH DESIGN AND METHODS:Twenty-nine patients (age, 24.0 ± 5.1 year...

journal_title：Diabetes technology & therapeutics

authors： Lebenthal Y,Lazar L,Benzaquen H,Shalitin S,Phillip M

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:Relatively little is known about parents' or children's attitudes toward recruitment for, and participation in, studies of new diabetes technologies immediately after diagnosis. This study investigated factors affecting recruitment of participants for studies in newly diagnosed youth with type 1 diabetes. M...

journal_title：Diabetes technology & therapeutics

authors： Farrington C,Allen J,Tauschmann M,Randell T,Trevelyan N,Hovorka R

更新日期：2016-09-01 00:00:00

abstract：OBJECTIVE:This study was designed to assess whether waist circumference can predict metabolic syndrome abnormalities in primary schoolchildren. RESEARCH DESIGN AND METHODS:Of 5,103 children (2,526 males) 4-13 years old who underwent anthropometric measurements, 530 had more extensive testing. Body mass index (BMI), wa...

journal_title：Diabetes technology & therapeutics

authors： Hirschler V,Maccallini G,Calcagno M,Aranda C,Jadzinsky M

更新日期：2007-04-01 00:00:00

abstract：:Quantifying body fat is currently an area of active research. Recent studies have shown that the quantity and location of fat in different compartments have varying clinical significance. This information can now be obtained from computed tomography (CT) or magnetic resonance (MR), and it can inform clinical decision ...

journal_title：Diabetes technology & therapeutics

authors： Garg K,Chang S,Scherzinger A

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:Computer simulation environments have been used in the development of many artificial pancreas systems. A glucose sensor model is an essential part of these environments, and different models have been proposed. However, not one of these models accounts for drop-outs of sensor readings, a well-known phenomen...

journal_title：Diabetes technology & therapeutics

authors： Emami A,Rabasa-Lhoret R,Haidar A

更新日期：2015-06-01 00:00:00

abstract：BACKGROUND:A1chieve(®) (Novo Nordisk A/S, Bagsværd, Denmark) was a prospective, multicenter, noninterventional study in 66,726 people with type 2 diabetes mellitus (T2DM) in 28 countries beginning biphasic insulin aspart 30 (aspart premix), insulin detemir, or insulin aspart in routine clinical care. SUBJECTS AND METH...

journal_title：Diabetes technology & therapeutics

authors： Shah S,Yang W,Hasan MI,Malek R,Molskov Bech O,Home P

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:This study was designed to validate the use of SoloSTAR (sanofi-aventis Deutschland GmbH, Frankfurt, Germany), a new disposable pen developed for use with insulin glargine by patients with type 1 or type 2 diabetes. METHODS:This single-center, open-label, single-arm, sequential trial enrolled subjects with ...

journal_title：Diabetes technology & therapeutics

authors： Schwartz S,Vlajnic A

更新日期：2008-10-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring is a useful tool for the achievement of improved glucose control in patients with diabetes. We tested the ability of a novel noninvasive continuous glucose monitor to track glucose excursions. METHODS:The novel noninvasive Aprise sensor (Glucon Inc., Boulder, CO) utilizes the p...

journal_title：Diabetes technology & therapeutics

authors： Weiss R,Yegorchikov Y,Shusterman A,Raz I

更新日期：2007-02-01 00:00:00

abstract：: Background: Continuous glucose monitoring (CGM) is a method of estimating blood glucose values from those recorded in the interstitial fluid. Because increasingly longer CGM measurements are possible, errors and data loss become more and more likely and potentially more da...

journal_title：Diabetes technology & therapeutics

authors： Kucharski P,Pagacz K,Szadkowska A,Młynarski W,Romanowski A,Fendler W

更新日期：2018-12-01 00:00:00

abstract：OBJECTIVE:Over the past 35 years considerable research has been performed toward the investigation of noninvasive and minimally invasive glucose monitoring techniques. Optical polarimetry is one noninvasive technique that has shown promise as a means to ascertain blood glucose levels through measuring the glucose conce...

journal_title：Diabetes technology & therapeutics

authors： Pirnstill CW,Malik BH,Gresham VC,Coté GL

更新日期：2012-09-01 00:00:00

abstract：:Empowerment plays significant roles in the complex management of type 2 diabetes. International guidelines have provided recommendations on management of Muslims who fast during Ramadan. However, there remains a lack of patient-centered epistemic tool to empower healthcare providers and patients in managing diabetes d...

journal_title：Diabetes technology & therapeutics

authors： Lum ZK,See Toh WY,Lim SM,Rusli KDB,Abdul Shakoor SAKK,Tsou KYK,Chew DEK,Dalan R,Kwek SC,Othman N,Lian JX,Lee JY

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:Real-time continuous glucose monitoring (CGM) was studied in 140 adults with diabetes over a 12-week period of home use. Hemoglobin A(1c)(HbA1c) was measured on day 1 (baseline) and at weeks 6 and 12. METHODS:On day 1, participants received the CGM device (STS(R) System, DexCom, Inc., San Diego, CA) and und...

journal_title：Diabetes technology & therapeutics

authors： Bailey TS,Zisser HC,Garg SK

更新日期：2007-06-01 00:00:00

abstract：: Background: Glycemic variability (GV) is an important component of glycemic control for patients with type 1 diabetes (T1D). The inadequacy of existing measurements lies in the fact that they view the variability from different aspects, so that no consensus has been reache...

journal_title：Diabetes technology & therapeutics

authors： Zheng F,Jalbert M,Forbes F,Bonnet S,Wojtusciszyn A,Lablanche S,Benhamou PY

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) technologies report measurements of interstitial glucose concentration every 5 min. CGM technologies have the potential to be utilized for prediction of prospective glucose concentrations with subsequent optimization of glycemic control. This article outlines a feed-forwar...

journal_title：Diabetes technology & therapeutics

authors： Pappada SM,Cameron BD,Rosman PM,Bourey RE,Papadimos TJ,Olorunto W,Borst MJ

更新日期：2011-02-01 00:00:00

abstract：OBJECTIVE:The purpose of the present study was to determine the effectiveness of a fluorescent contact lens glucose sensor in monitoring glucose in patients with diabetes. METHODS:Under an institutional review board-approved protocol, five fasting patients with type II diabetes were given a challenge consisting of 75 ...

journal_title：Diabetes technology & therapeutics

authors： March WF,Mueller A,Herbrechtsmeier P

更新日期：2004-12-01 00:00:00

abstract：:On May 26, 1976, the Food and Drug Administration (FDA) began implementing the Medical Device Amendments to the Federal Food Drug and Cosmetic Act. These amendments give FDA specific authority to regulate "medical devices." Additional authority was provided in the Safe Medical Devices Act of 1990. The pathways to get ...

journal_title：Diabetes technology & therapeutics

authors： Gutman S,Bernhardt P,Pinkos A,Moxey-Mims M,Knott T,Cooper J

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVE:this study assessed patient-related factors associated with persistence and resumption of using pens as insulin delivery devices. METHODS:patients (n = 549; 300 current pen users, 249 former pen users) were recruited from national panels to participate in computer-assisted telephone interviews. Measures incl...

journal_title：Diabetes technology & therapeutics

authors： Peyrot M,Rubin RR

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Insulin pumps (for continuous subcutaneous insulin infusion [CSII]) are used widely in type 1 diabetes mellitus. Although there has been considerable study of outcomes, there are few recent data on CSII-associated adverse events and no data on family perceptions of adverse events and their confidence in deal...

journal_title：Diabetes technology & therapeutics

authors： Wheeler BJ,Donaghue KC,Heels K,Ambler GR

更新日期：2014-04-01 00:00:00

abstract：BACKGROUND:Persistent use of real-time continuous glucose monitoring (CGM) improves diabetes control in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D). METHODS:PRECISE II was a nonrandomized, blinded, prospective, single-arm, multicenter study that evaluated the accuracy and safety of the implantable...

journal_title：Diabetes technology & therapeutics

authors： Christiansen MP,Klaff LJ,Brazg R,Chang AR,Levy CJ,Lam D,Denham DS,Atiee G,Bode BW,Walters SJ,Kelley L,Bailey TS

更新日期：2018-03-01 00:00:00

abstract：BACKGROUND:Prediction of glycemic profile is an important task for both early recognition of hypoglycemia and enhancement of the control algorithms for optimization of insulin infusion rate. Adaptive models for glucose prediction and recognition of hypoglycemia based on statistical and artificial intelligence technique...

journal_title：Diabetes technology & therapeutics

authors： Daskalaki E,Prountzou A,Diem P,Mougiakakou SG

更新日期：2012-02-01 00:00:00